ReShape Lifesciences Inc
NASDAQ:RSLS
ReShape Lifesciences Inc
Research & Development
ReShape Lifesciences Inc
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
Research & Development
-$2.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Research & Development
-$1.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-9%
|
|
Boston Scientific Corp
NYSE:BSX
|
Research & Development
-$1.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
Stryker Corp
NYSE:SYK
|
Research & Development
-$1.3B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
Abbott Laboratories
NYSE:ABT
|
Research & Development
-$2.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Research & Development
-$1B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-20%
|
See Also
What is ReShape Lifesciences Inc's Research & Development?
Research & Development
-2.3m
USD
Based on the financial report for Dec 31, 2023, ReShape Lifesciences Inc's Research & Development amounts to -2.3m USD.
What is ReShape Lifesciences Inc's Research & Development growth rate?
Research & Development CAGR 5Y
26%
Over the last year, the Research & Development growth was 9%. The average annual Research & Development growth rates for ReShape Lifesciences Inc have been 2% over the past three years , 26% over the past five years .